Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We explored results among study participants with diabetes. Among 2,516 randomized participants, 181 (7.2%) had diabetes. Of 166 participants with diabetes in the microbiologically eligible analysis group, 26.3% (15/57) had unfavorable outcomes in the control regimen, 13.8% (8/58) in the rifapentine/moxifloxacin regimen, and 29.4% (15/51) in the rifapentine regimen. The difference in proportion of unfavorable outcomes between the control and rifapentine/moxifloxacin arms in the microbiologically eligible analysis group was -12.5% (95% CI -27.0% to 1.9%); the difference between the control and rifapentine arms was 3.1% (95% CI -13.8% to 20.0%). Safety outcomes were similar in the rifapentine/moxifloxacin regimen and control arms. Among participants with TB and diabetes, the rifapentine/moxifloxacin arm had fewest unfavorable outcomes and was safe. Our findings indicate that the rifapentine/moxifloxacin regimen can be used in persons with TB and diabetes.
Authors
- Rodney Dawson (ORCID: https://orcid.org/0000-0001-9804-1588)
- Radojka M. Savić (ORCID: https://orcid.org/0000-0003-3143-5579)
- Kelly E. Dooley (ORCID: https://orcid.org/0000-0001-9013-5256)
- Payam Nahid (ORCID: https://orcid.org/0000-0003-2811-1311)
- Ziyaad Waja (ORCID: https://orcid.org/0000-0001-8717-9039)
- Patrick P. J. Phillips (ORCID: https://orcid.org/0000-0002-6336-7024)
- Nigel Scott (ORCID: https://orcid.org/0000-0002-2132-793X)
- William C. Whitworth (ORCID: https://orcid.org/0000-0001-5306-548X)
- Wadzanai Samaneka (ORCID: https://orcid.org/0000-0003-0215-9309)
- Susan Swindells (ORCID: https://orcid.org/0000-0001-5826-6037)
- Erin Sizemore (ORCID: https://orcid.org/0000-0003-3232-0546)
- Wendy Carr
- Kia Bryant (ORCID: https://orcid.org/0000-0003-0785-7800)
- Richard E. Chaisson (ORCID: https://orcid.org/0000-0003-4710-925X)
- Lakshmi Praveena Peddareddy
- Melissa Engle
- Sandra Wagner Cardoso (ORCID: https://orcid.org/0000-0001-5230-0003)
- Nguyen Viet Nhung (ORCID: https://orcid.org/0000-0002-5447-133X)
- Ekaterina V. Kurbatova (ORCID: https://orcid.org/0000-0003-4636-3731)
- Susan E. Dorman (ORCID: https://orcid.org/0000-0001-6882-9470)
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2025-03-01
- DOI
- https://doi.org/10.3201/eid3103.241634
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40